智通财经APP获悉，科济药业-B(02171)涨近7%，截至发稿，涨4.74%，报15.92港元，成交额1.01亿港元。
消息面上，科济药业近日宣布，公司自主研发的舒瑞基奥仑赛注射液（研发代码：CT041）已被国家药品监督管理局药品审评中心纳入突破性治疗药物品种名单，拟定适应症为既往接受过至少二线治疗失败的Claudin18.2表达阳性的晚期胃/食管胃结合部腺癌。公司预计将于2025年上半年向国家药品监督管理局递交舒瑞基奥仑赛注射液的新药上市申请。
值得注意的是，2月26日，科济药业公告披露，旗下优恺泽生物完成珠海软银主导的8000万元战略融资，对应估值达10亿元。此次增资完成后，公司的权益将由100%稀释至92%。优恺泽专注于利用通用型CAR-T细胞疗法治疗血液瘤，获得了相关产品在中国内地的研发、生产与商业化的独家权利。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.